Corina N.A.M. Oldenhuis

Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Constantijne H. Mom, Jaap Verweij, Corina N.A.M. Oldenhuis et al. · Clinical Cancer Research · 2009 · 104 citations

Medicine, Oncology, Pharmacology +17

Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study

Suzanna J. Schraa, Karlijn L. van Rooijen, Dave E. W. van der Kruijssen et al. · BMC Cancer · 2020 · 59 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors

Sunil Sharma, Elisabeth G.E. de Vries, Jeffrey R. Infante et al. · Investigational New Drugs · 2013 · 53 citations

Medicine, Oncology, Pharmacology +14

Sulindac Inhibits β-Catenin Expression in Normal-Appearing Colon of Hereditary Nonpolyposis Colorectal Cancer and Familial Adenomatous Polyposis Patients

Jan J. Koornstra, Fleur E.M. Rijcken, Corina N.A.M. Oldenhuis et al. · Cancer Epidemiology Biomarkers & Prevention · 2005 · 34 citations

Medicine, Oncology, Pharmacology +17

Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors

Shringi Sharma, Elisabeth G.E. de Vries, J. R. Infante et al. · Journal of Clinical Oncology · 2008 · 25 citations

Medicine, Oncology, Pharmacology +17